James J. Mahoney

Internal Medicine

1690 Crown Colony Dr
Quincy, MA 02169

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3 publications

Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment.

Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment.

Journal: NPJ precision oncology

Published: June 24, 2024

First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.

First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.

Journal: Communications medicine

Published: March 31, 2023

Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors.

Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors.

Journal: Communications medicine

Published: February 23, 2023

Showing 1-3 of 3

Last Updated: 09/26/2026